Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101

- Issued patents include important claims covering methods of treating cancer using MIE-101 as a single agent or in combination with other treatment modalities -

- MIE-101 has demonstrated potent, durable, and systemic antitumor activity in multiple preclinical tumor models and in naturally occurring canine tumors -

NOVATO, CA / ACCESSWIRE / April 11, 2023 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent cancer, today announced that the US Patent and Trademark Office (USPTO) has issued an additional patent to protect the technology behind Mosaic's lead immuno-oncology product candidate, MIE-101. Co-inventors of the newly patented technology include Mosaic co-founders Nicole F. Steinmetz, Ph.D., professor of NanoEngineering and director of the UC San Diego Center for Nano-ImmunoEngineering, and Steven N. Fiering, Ph.D., professor of microbiology and immunology at the Dartmouth Geisel School of Medicine.

"These patents provide important protection for the continued development of our lead immunotherapy candidate, MIE-101, derived from CPMV, and is a key component of our intellectual property covering the use of this first-in-class immune stimulant to fight cancer," said Steven King, president and chief executive officer of Mosaic. "The patents together add significant value to our intellectual property portfolio as we continue to advance our lead program. We look forward to continuing to translate the research of Mosaic co-founders Drs. Steinmetz and Fiering toward clinical development in humans and for the treatment of companion animals with cancer."

U.S. Patent No. 11,617,787 was recently issued to Case Western Reserve University ("CWRU") and Dartmouth College. The new patent builds on the key U.S. patent issued in 2022, U.S. Patent No. 11,260,121, which is the foundation of the patent portfolio in the United States. Both patents are covered under an exclusive worldwide license agreement between Mosaic and CWRU, granting the Company the exclusive rights to the technology.

The claims of both patents include methods of treating cancer by administering a plant-derived viral nanoparticle, known as cowpea mosaic virus (CPMV), directly into solid tumors, such as by intratumoral injection or by inhalation, in the case of lung cancer. U.S. Patent No. 11,260,121 broadly covers the treatment of human and animal patients, whereas U.S. Patent No. 11,617,787 is specifically directed to veterinary treatment. The claims of both patents cover the administration of CPMV either as a single agent therapy, or in combination with other treatments to a patient suffering from primary or metastatic cancer. Combination regimens broadly include the administration of CPMV with radiation, chemotherapy and immunotherapy.